MoonLake Immunotherapeutics (MLTX) · Nov 4, 2026 · Earnings

MoonLake earnings miss as BLA progress extends cash runway

Miss — Diluted EPS $(0.93) vs ~$0.77 consensus loss

MoonLake’s Q3 earnings missed consensus as BLA-related costs rose, but the company extended its projected cash runway into mid-2028.

MoonLake is moving sonelokimab from late-stage development toward a potential U.S. launch in hidradenitis suppurativa, while keeping its broader psoriatic arthritis program active. The BLA filing itself was already expected for late September, and the company had previously projected FDA acceptance and a Priority Review decision by the end of November 2026.

The quarter missed on earnings, largely because regulatory costs arrived early. Diluted EPS was $(0.93), versus a published consensus loss of roughly $0.77, and the net loss widened from $(61.8) million in the prior quarter to $(79.5) million. The main driver was an $18.7 million increase in R&D expense tied to an accrued milestone license fee associated with expected BLA acceptance, making this a cost-timing miss rather than evidence of a broad collapse in development execution. The consensus estimate is externally sourced; the filing identifies the milestone accrual as the main expense driver.

Q3 2026Q2 2026Consensus / prior outlook
Diluted EPS (Income Statement)$(0.93)$(0.84)$(0.77)
R&D expense (Income Statement)$68.9M$50.2M
Cash, equivalents and securities (Financial Highlights)$498.5M$537.0M
Cash runway (Financial Highlights)mid-2028end-2027

The business milestone is real but not a surprise. MoonLake submitted the HS BLA on September 30, 2026, covering adults and adolescents aged 12 and older; the filing now formally confirms that regulatory transition and says FDA acceptance is expected within approximately 60 days.

Funding risk looks somewhat better despite the quarterly cash burn. Reported liquidity fell to $498.5 million from roughly $537.0 million in the prior quarter, but management extended its stated cash runway from the previously projected end of 2027 to mid-2028 and still has up to $400 million available under its Hercules debt facility. That improves the financing picture, although the longer runway is a company projection rather than cash already secured.

The clinical pipeline remains on schedule rather than newly upgraded. IZAR-2 enrollment was completed, with initial topline results still expected in the first quarter of 2027, while the positive IZAR-1 readout and HS efficacy data were already public before this release.

Bottom line: This is a mixed update: the regulatory path and funding runway advance, but the earnings miss and higher near-term costs make the quarter modestly weaker than expected. The filing supports the existing launch story more than it rewrites it.

What to watch next

FDA BLA acceptance and review timeline, expected by late November

Original filing on SEC EDGAR

More MoonLake Immunotherapeutics news

MoonLake earnings miss as BLA progress extends cash runway | MLTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.